Seattle Genetics, which has been offering innovative antibody-based therapies for cancer treatment, is a leading research institute in the areas of biotechnology. It is the leader in the industry for offering antibody-drug conjugates (ADCs), a new technology that is designed to capture the targeting ability of monoclonal antibodies to get cell-killing agents that are able to take on cancer cells. The technology also ensures non-targeted cells are spared in the process to ensure the patient does not suffer extreme conditions during treatment.
Seattle Genetics has been developing a clinical pipeline through research and investment. This effort has led to the successful development of stable linkers and cell-killing drugs that are potent. The process helps to identify novel antigen targets and antibodies that can be useful in the treatment of cancer. Research has also been helpful in advancing engineering initiatives suitable for antibody activities.
This effort is also targeting identifying and developing monoclonal antibodies as well as ADCs that bear novel specificities against specific antigens. Seattle Genetics emphasizes on proteins that are prevalent in cancer to detect those that are located beneath cancer cells. This is followed by the development of screen panels that feature cancer-reactive antibodies in the labs.
Advancing ADC Technology
Antibody-drug conjugate technology works by empowering monoclonal antibody activities in the treatment of cancer. Having been in operation for more than a decade researching on this topic, Seattle Genetics has been able to come up with synthetic cytotoxic agents and tumor-associated antigens that have been useful in the treatment of cancer.
The Seattle Genetics’ Clinical Trials is a research program that invites individuals for research to detect, diagnose, prevent and treat certain diseases. This program contributes to the knowledge of scientists about cancer and provides useful data for improvement of treatment procedures.
Leadership: Clay B. Siegall, Ph.D.
In 1998, Clay Siegall co-founded Seattle Genetics and is the current president of the company. His educational background in science and biotechnology has been useful in leading the company to emerge a leader in the industry. He is always inspired by the need to fulfill needs through research and innovation, something he has transferred to Seattle Genetics. Under Siegall’s leadership, Seattle Genetics has signed multiple licenses and has expanded its product pipeline.